GUANGZHOU WONDFO BIOTECH CO.,LTD Financials Guangzhou Wondfo Biotech Co.,Ltd
Equities
300482
CNE100002102
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.85 CNY | +3.65% |
|
-2.56% | -14.32% |
| 05-29 | Guangzhou Wondfo Biotech Co.,Ltd Announces Final Cash Dividend (A Shares) for Year 2023, Payable on June 5, 2024 | CI |
| 05-06 | Wondfo Biotech's Unit Gets Emergency Use Authorization from US FDA | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 17,741 | 30,571 | 17,522 | 14,088 | 13,338 | 12,103 | - | - |
| Enterprise Value (EV) 1 | 17,741 | 30,571 | 17,522 | 14,088 | 13,338 | 12,103 | 12,103 | 12,103 |
| P/E ratio | 45.7 x | 47.7 x | 27.5 x | 11.8 x | 27.4 x | 18.8 x | 15.3 x | 12 x |
| Yield | 0.48% | - | - | - | 1.33% | 1.16% | 1.47% | - |
| Capitalization / Revenue | 8.49 x | 10.9 x | 5.21 x | 2.48 x | 4.82 x | 3.7 x | 3.08 x | 2.53 x |
| EV / Revenue | 8.49 x | 10.9 x | 5.21 x | 2.48 x | 4.82 x | 3.7 x | 3.08 x | 2.53 x |
| EV / EBITDA | 28.6 x | 34.5 x | 19.9 x | 8.7 x | 16.5 x | 12.9 x | 10.5 x | 8.55 x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | 7.98 x | 11.2 x | 5.4 x | 3.34 x | 3.04 x | 2.15 x | 1.91 x | 1.63 x |
| Nbr of stocks (in thousands) | 445,502 | 445,485 | 444,952 | 442,034 | 442,084 | 468,218 | - | - |
| Reference price 2 | 39.82 | 68.62 | 39.38 | 31.87 | 30.17 | 25.85 | 25.85 | 25.85 |
| Announcement Date | 28/02/20 | 30/03/21 | 24/04/22 | 30/03/23 | 21/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,091 | 2,811 | 3,361 | 5,681 | 2,765 | 3,268 | 3,936 | 4,775 |
| EBITDA 1 | 620.8 | 885.5 | 881.6 | 1,619 | 806.2 | 936 | 1,157 | 1,415 |
| EBIT 1 | 500.2 | 740.1 | 691.9 | 1,368 | 549.1 | 735.7 | 928.4 | 1,149 |
| Operating Margin | 23.92% | 26.33% | 20.59% | 24.08% | 19.86% | 22.51% | 23.59% | 24.05% |
| Earnings before Tax (EBT) 1 | 502.2 | 730.9 | 680.5 | 1,365 | 540.8 | 729.6 | 922.8 | 1,143 |
| Net income 1 | 385.1 | 634.2 | 634.4 | 1,197 | 487.6 | 650.4 | 793.8 | 1,013 |
| Net margin | 18.42% | 22.56% | 18.88% | 21.07% | 17.64% | 19.9% | 20.17% | 21.22% |
| EPS 2 | 0.8722 | 1.438 | 1.430 | 2.710 | 1.100 | 1.378 | 1.695 | 2.146 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | 0.1923 | - | - | - | 0.4000 | 0.3000 | 0.3800 | - |
| Announcement Date | 28/02/20 | 30/03/21 | 24/04/22 | 30/03/23 | 21/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 515.8 | 760.5 | 861.1 | 819 | 655 | 852 |
| EBITDA | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - |
| Net income | 130.8 | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - |
| EPS | 0.3000 | 0.1500 | 0.1900 | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 15/08/23 | 25/10/23 | 21/04/24 | 22/04/24 | - | - | - |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 18.7% | 25.1% | 20.6% | 30.8% | 10.9% | 11.4% | 12.9% | 14% |
| ROA (Net income/ Total Assets) | - | 17.5% | 13.8% | - | 8.08% | 9.1% | 10% | 11% |
| Assets 1 | - | 3,625 | 4,581 | - | 6,037 | 7,147 | 7,938 | 9,211 |
| Book Value Per Share 2 | 4.990 | 6.140 | 7.290 | 9.530 | 9.920 | 12.00 | 13.60 | 15.90 |
| Cash Flow per Share 2 | 0.7000 | 2.380 | 1.490 | 3.780 | 0.7400 | 1.900 | 1.900 | 2.380 |
| Capex 1 | 179 | 419 | 456 | 583 | 432 | 435 | 451 | 480 |
| Capex / Sales | 8.57% | 14.92% | 13.58% | 10.26% | 15.62% | 13.31% | 11.45% | 10.05% |
| Announcement Date | 28/02/20 | 30/03/21 | 24/04/22 | 30/03/23 | 21/04/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
25.85
CNY
Average target price
36.3
CNY
Spread / Average Target
+40.41%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.32% | 1.67B | |
| -9.64% | 11.57B | |
| -12.79% | 7.37B | |
| +26.65% | 5.44B | |
| -17.87% | 3.74B | |
| +7.41% | 2.58B | |
| -65.15% | 2.33B | |
| +28.63% | 2.23B | |
| -11.30% | 2.21B | |
| -9.41% | 1.4B |
- Stock Market
- Equities
- 300482 Stock
- Financials Guangzhou Wondfo Biotech Co.,Ltd
